# Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

> **NCT00740636** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 92 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00740636
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2016-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740636, "Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00740636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*